Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The aim of the project is to increase the innovation of Selvita and to increase the internationalisation of scientific research and development by introducing new molecules potentially used in the treatment of solid tumours into the Company’s activities, with particular emphasis on breast and brain cancers. From a scientific point of view, these will be minor inhibitors of Melk protein kinase activity. Melk kinase belongs to the family of protein kinases involved in the transmission of intracellular signals whose disorders are related to the process of cancer. Its level is significantly elevated in cancers of various types – breast, brain, colon, ovaries, lungs and many others, while it is almost completely absent in normal cells. Its increased levels negatively correlate with the survival of patients with breast and brain cancer, and decreased expression or activity results in inhibition of tumour cell proliferation both in vitro and in vivo. As part of the project, we plan to develop new inhibitors that inhibit Melk kinase activity based mainly on a series of strong and selective leading compounds (melka inhibitors studied mainly in cellular systems) developed so far in Selvita laboratories. In addition to the greater effectiveness of personalised pharmacotherapy, these molecules will have a high safety of use thanks to the specificity of the action. The selected molecular target gives a good chance of getting the first drug in its class. The development of pivotal compounds will be fully characterised by pharmacodynamic and pharmacokinetic characteristics.